Emerging biomarker studies suggest that complement proteins in blood and cerebrospinal fluid may aid in distinguishing AD patients and predicting disease progression; however, further replication and standardization are needed before these markers can be considered reliable biomarkers for clinical use.27, 28. Here, VTN is linked to Alzheimer disease.